ChromaDex to Host Symposium on NAD+ in Human Health and Disease at NUTRITION 2020 LIVE ONLINE Annual Meeting

ChromaDex Corp. (NASDAQ:CDXC) announced today it has organized a virtual symposium entitled “Nicotinamide Adenine Dinucleotide (NAD⁺) in Human Health and Disease: The State of the Science on Nutrition Interventions” tomorrow Tuesday, June 2, from 8:30 to 10:00 AM EDT at NUTRITION 2020 LIVE ONLINE, the annual meeting hosted by the American Society for Nutrition (ASN).

“We are pleased to organize this NAD⁺ symposium for leading nutrition research scientists and clinicians around the world,” said Dr. Andrew Shao, Senior Vice President of Global Scientific and Regulatory Affairs for ChromaDex. “As a science-based company and innovators behind Niagen®, our mission is to further explore the full potential of NAD⁺ and its impact on cellular resilience and human health. We are pleased to continue the practice of making Niagen freely available to the nutrition research community through our industry leading ChromaDex External Research Program (CERP).”

The satellite program will focus on the latest findings on NAD⁺ and human health and disease and how maintaining or raising NAD⁺ levels contributes to resilience. Scientific thought leaders will participate in a panel to discuss the available literature demonstrating the effect of dietary NAD⁺ precursors on NAD⁺ levels and health outcomes.

Discussion topics and panel participants are as follows:

• Opening remarks from the session Co-chair: Framing the issue – Why should we care about NAD⁺? – Rong Tian, MD, PhD, Professor and Director, Mitochondria and Metabolism Center, University of Washington

• A summary of recent findings on NAD⁺ in human health and disease – Charles Brenner, PhD, University of Iowa, ChromaDex Chief Scientific Advisor and recipient of the 2020 ASN Mary Swartz Rose Senior Investigator award

• Comparing and contrasting NAD⁺ precursors: A review of mechanisms – Carles Cantó, PhD, Nestlé Institute of Health Sciences, Lausanne, Switzerland

• Emerging effects of NAD⁺ precursors in humans: The current state of clinical research – Kevin C. Maki, PhD, CLS, FNLA, FTOS, FACN, President and Chief Scientist, MB Clinical Research and Consulting, LLC

“With a variety of NAD⁺ precursors being studied around the world, I look forward to a rich discussion on mechanistic differences amongst precursors and their important role in biological functions,” said Nestlé researcher Carles Cantó, PhD, who published a paper in Nature Communications last year highlighting the unique properties of nicotinamide riboside (NR) over other NAD⁺ precursors.

NUTRITION 2020 LIVE ONLINE is hosted by the American Society for Nutrition (ASN), the preeminent professional organization for nutrition research scientists and clinicians around the world.

For more information and to register for the meeting, please click here.

For additional information on ChromaDex, please visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN^® nicotinamide riboside, sold directly to consumers as TRU NIAGEN^®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN^® is helping the world AGE BETTER^®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as amended, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200601005102/en/

ChromaDex Media Contact:
Alex Worsham, Senior Director of Global Corporate Communications
310-388-6706 ext. 689
[email protected]

ChromaDex Investor Relations Contact:
Brianna Gerber, Vice President of FP&A and Investor Relations
949-419-0288 ext. 127
[email protected]